O’Brien, S., Furman, R.R., Coutre, S., Flinn, I.W., Burger, J.A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., Heerema, N.A., Johnson, A.J., Luan, Y., James, D.F., Chu, A.D. and Byrd, J.C. (2018) Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience. Blood, 131, 1910-1919.
https://doi.org/10.1182/blood-2017-10-810044

has been cited by the following article:

• TITLE: A Rare Entity of Accelerated Chronic Lymphocytic Leukemia: A Report of Two Cases and Review of Literature

  AUTHORS: Zahra Kmira, Ben Yahya Noura, Chembah Wafa, Ben Sayed Nesrine, Chiba Dorra, Bouteraa Walid, Zaier Monia, Ben Youssef Yosra, Haifa Regaieg, Khelif Abderrahim

  KEYWORDS: Accelerated Chronic Lymphocytic Leukemia, Richter Transformation, Prognosis, Treatment

  JOURNAL NAME: Health, Vol.15 No.8, August 22, 2023

  ABSTRACT: Background: Accelerated-chronic lymphocytic leukemia (A-CLL) is a rare disease entity as it represents less than 1% of all reported cases of chronic lymphoid leukemia (CLL). Moreover, it is most likely an under diagnosed entity due to its rarity and the non-standardized practice of lymph node biopsy in CLL. Purpose: The aims of our work are to establish the diagnosis of A-CLL and to study the prognosis and treatment of this rare entity. Method: here, we report the clinical presentation and the follow up of two cases of A-CLL. Results: Distinguishing Richter transformation (RT) from A-CLL is important as it may result in a major change in disease management. The prognosis of A-CLL is intermediate between CLL and RT. The prognosis is mainly poor due to a predominance of poor prognostic markers including an increasing number of p53-positive cases. Conclusion: To this date, no prospective study has been led to define the best treatment for A-CLL. The shorter survival of A-CLL when compared to typical CLL implies the need of a more aggressive treatment.